Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-Stage Renal Disease.

Trial Profile

Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-Stage Renal Disease.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Aug 2015

At a glance

  • Drugs Anti-digoxin polyclonal antibody (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2012 Planned End Date changed from 1 Feb 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 24 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 May 2009 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top